PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 31, 2026Journal of Cancer Research and Clinical Oncology0 citationsOpen Access

Diving into the transcriptional landscape of leukemic stem cells in acute myeloid leukemia at single-cell resolution

ZRZuzanna RzetelskaLGLidia GilFBFrancesco Buccisano

Key Points

  • This review aims to summarize transcriptomic studies on leukemic stem cells in acute myeloid leukemia.
  • Identified literature through a PubMed search
  • Analyzed 27 studies on leukemic stem cells biology
  • Covered aspects like gene regulation and metabolic reprogramming
  • Highlighted complexity of leukemic stem cells, including quiescent and plastic states
  • Revealed metabolic shifts from glycolysis to lipogenesis
  • Identified potential therapeutic targets for eradicating leukemic stem cells

Abstract

Abstract Purpose The aim of this review is to summarize transcriptomic studies using single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq to investigate leukemic stem cells (LSCs) population in acute myeloid leukemia (AML). Methods Literature for inclusion was identified through a PubMed search. Twenty-seven studies were analyzed, covering various aspects of LSCs biology, including epigenetic, transcriptional, and translational gene regulation, metabolic reprogramming or cellular differentiation. Results The reviewed studies highlight the complexity of LSCs, including their quiescent state, state-to-state cellular plasticity, and metabolic reprogramming from glycolysis to lipogenesis. Comparative analyses of matched diagnostic and post-treatment samples provide insights into the dynamic behavior of LSCs during therapy. The findings also identify potential therapeutic targets and strategies to selectively eradicate LSCs. Conclusion Single-cell RNA sequencing technologies offer unprecedented resolution for studying LSCs in AML, revealing cellular heterogeneity and dynamic evolution within these critical populations. Despite these advances, standardized criteria for LSCs identification are still needed, and longitudinal studies at clinically relevant time points are essential to fully understand their role in disease progression and therapy resistance. Such approaches may ultimately uncover novel therapeutic vulnerabilities and improve clinical management of AML.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Rzetelska et al. (2026) studied this question.

synapsesocial.com/papers/6a1bd1745783ba022b6fcfa4https://doi.org/10.1007/s00432-026-06500-1
Ask AI
Helpful
Bookmark
Share
View Full Paper